Related Experiment Video
Updated: May 12, 2026
Direct Reprogramming of Mouse Fibroblasts into Melanocytes
Published on: August 27, 2021
MitoQ for vitiligo by mitigating PARP1 translocation aberrations: Network pharmacology and experimental validation
Renxue Xiong1, Shiyu Jin2, Yujie Li2
1Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China; Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.
Purpose:
Oxidative stress plays a significant role in the development of vitiligo. Although the specific mechanism of the mitochondria-targeted antioxidant mitoquinone (MitoQ) in vitiligo remains unclear, it has shown promise in the treatment of various diseases.
Methods:
In this study, we employed network pharmacology, molecular docking, transcriptomic approaches, and experimental verification to investigate the potential targets of MitoQ in vitiligo.
Results:
Molecular docking results identified four possible crucial targets of MitoQ in vitiligo treatment: poly (ADP-ribose) polymerase 1 (PARP1), prostaglandin-endoperoxide synthase 2 (PTGS2), estrogen receptor 1 (ESR1), and C-X-C motif chemokine receptor 3 (CXCR3). MitoQ alleviated oxidative stress-induced PARP1 nuclear mislocalization, attenuated ROS accumulation, restored mitochondrial membrane potential, and enhanced ATP synthesis in vitro analysis. Transcriptomic analysis demonstrated that MitoQ reduced the expression of DNA damage genes and genes involved in the PI3K-AKT and MAPK signaling pathways. The protein-protein interaction network indicated a potential relationship between PARP1 and DNA damage-related genes, suggesting that MitoQ could interfere with abnormal PARP1 activation. Notably, MitoQ reduced cellular senescence by decreasing CDKN1A/p21 protein through PARP1, and the knockdown of PARP1 reduced oxidative damage.
Conclusion:
These results indicate that PARP1 decreases cellular senescence and offers a potential target for therapeutic research in the management of vitiligo.
